Data Are Mean Standard Deviation Unless Otherwise Indicated

Apostolidis_WJUR2691

Supplementary Table 1 Baseline demographics and disease characteristics (modified intent-to-treat population)

Characteristic / Placebo
(n = 16) / OnabotA 50 U
(n = 19) / OnabotA 100U
(n = 21) / OnabotA 200U
(n = 17)
Age (yr)s / 33.6 ± 9.0 / 31.2 ± 7.6 / 36.7 ± 11.7 / 33.6 ± 10.8
Gender, male [n (%)] / 15 (93.8) / 17 (89.5) / 17 (81.0) / 14 (82.4)
SCI characteristics
Type of injury [n (%)]
Trauma / 16 (100.0) / 19 (100.0) / 20 (95.2) / 17 (100.0)
Stable focal mechanical compression / 0 / 0 / 1 (4.8) / 0
ASIA impairment scalea [n (%)]
A / 8 (50.0) / 12 (63.2) / 5 (25.0) / 9 (52.9)
B / 3 (18.8) / 2 (10.5) / 3 (15.0) / 1 (5.9)
C / 1 (6.3) / 2 (10.5) / 5 (25.0) / 4 (23.5)
D / 4 (25.0) / 2 (10.5) / 6 (30.0) / 2 (11.8)
E / 0 / 1 (5.3) / 1 (5.0) / 1 (5.9)
Neurological injury [n (%)]
T1–T12 / 11 (68.8) / 14 (73.7) / 11 (52.4) / 12 (70.6)
L1–L5 / 5 (31.3) / 5 (26.3) / 10 (47.6) / 4 (23.5)
S1–S5 / 0 / 0 / 0 / 1 (5.9)
Urological medical history [n (%)]
Urinary tract infection / 8 (50.0) / 4 (21.0) / 4 (19.0) / 6 (35.3)
Asymptomatic bacteriuria / 0 / 0 / 1 (4.8) / 0
Calculus bladder / 3 (18.8) / 0 / 0 / 2 (11.8)
Nephrolithiasis / 0 / 0 / 2 (9.5) / 0
Median duration of NDO (mo) / 42.4 / 25.0 / 38.0 / 31.4
Anticholinergic use [n (%)] / 9 (56.3) / 9 (47.4) / 10 (47.6) / 6 (35.3)
Using CIC [n (%)] / 11 (68.8) / 13 (68.4) / 10 (47.6) / 13 (76.5)
UI episodes/week (n) / 24.6 ± 9.1 / 26.3 ± 19.3 / 37.8 ± 27.6 / 28.8 ± 20.3
MCC (mL) / 189.8 ± 103.6 / 213.9 ± 135.4 / 161.6 ± 66.1 / 214.2 ± 96.6
MDP during first IDC (cm H2O) / 45.9 ± 36.8 / 52.7 ± 39.5 / 54.2 ± 41.5 / 62.9 ± 72.1
Volume per void (mL) / 282.4 ± 85.1 / 246.6 ± 108.7 / 213.6 ± 84.7 / 223.9 ± 81.5

Data are mean ± standard deviation unless otherwise indicated

OnabotA onabotulinumtoxinA, SCI spinal cord injury, ASIA american American Sspinal Iinjury Aassociation, T thoracic, L lumbar, S sacral, NDO neurogenic detrusor overactivity, CIC clean intermittent catheterization, UI urinary incontinence, MCC maximum cystometric capacity, MDP maximum detrusor pressure, IDC involuntary detrusor contraction

aASIA impairment grade was not recorded for one patient in the onabotA 100U group